1. Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
- Author
-
Akira Endo, Kazuma Yamakawa, Takashi Tagami, Yutaka Umemura, Kyosuke Takahashi, Hiroki Nagasawa, Yuichi Araki, Mitsuaki Kojima, Toshiki Sera, Masayuki Yagi, Ryo Yamamoto, Jiro Takahashi, Masaki Nakane, Chikashi Takeda, Chihiro Narita, Satoshi Kazuma, Hiroko Okura, Hiroyuki Takahashi, Takeshi Wada, Shu Tahara, Ayaka Matsuoka, Todani Masaki, Atsushi Shiraishi, Keiichiro Shimoyama, Yuta Yokokawa, Rintaro Nakamura, Hisako Sageshima, Yuichiro Yanagida, Kunihiko Takahashi, and Yasuhiro Otomo
- Subjects
Arterial pressure ,Geriatrics ,Hypotension ,Sepsis ,Vasoconstrictor agents ,Medicine (General) ,R5-920 - Abstract
Abstract Background Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. Methods A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. Discussion The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. Trial registration UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020.
- Published
- 2022
- Full Text
- View/download PDF